Clinical Rheumatology

, Volume 32, Supplement 1, pp 97–101

Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener’s granulomatosis

  • Cord Huchzermeyer
  • Christian Mardin
  • Leonard Holbach
  • Jochen Zwerina
  • Georg Schett
  • Jürgen Rech
Case Report


A 56-year old patient with a history of limited Wegener's granulomatosis presented with signs and symptoms of optic neuritis. Radiologic signs of orbital inflammation were absent. Testing of visual acuity and visual field allowed close monitoring of disease activity. Thus, rapid improvement of visual function was achieved with high-dose steroids. Despite maintenance therapy with cyclophosphamide recurrence occurred repeatedly as soon as tapering of steroids was begun. After remission induction with rituximab, the patient retained good visual function under maintenance therapy with azathioprine and low-dose corticosteroids. Optic neuritis in Wegener's granulomatosis without signs of orbital involvement is rare and most likely caused by occlusive vasculitis of the vasa nervorum. In this patient with optic neuritis refractory to conventional therapy, rituximab in combination with cyclophosphamide and corticosteroids was well tolerated and successfully used for remission induction, followed by maintenance therapy with azathioprine and low dose corticosteroids.


Eye involvement Optic neuritis Remission induction Rituximab Wegener’s granulomatosis 


  1. 1.
    Sack KE (1989) Wegener’s granulomatosis. West J Med 150(3):329–333PubMedGoogle Scholar
  2. 2.
    Ahmad I, Lee WC, Nagendran V, Wilson F, Shortridge RT (2000) Localised Wegener’s granulomatosis in otolaryngology: a review of six cases. ORL J Otorhinolaryngol Relat Spec 62(3):149–155PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, Peel ET, Wood JB (1992) Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 83(302):427–438PubMedGoogle Scholar
  4. 4.
    Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA (1983) Ocular complications of Wegener’s granulomatosis. Ophthalmology 90(3):279–290PubMedGoogle Scholar
  5. 5.
    DeGroot KD, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461–2469CrossRefGoogle Scholar
  6. 6.
    Benenson E, Fries JW, Heilig B, Pollok M, Rubbert A (2005) High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 24(3):251–257PubMedCrossRefGoogle Scholar
  7. 7.
    Bosch X, López-Soto A, Morelló A, Olmo A, Urbano-Márquez A (1997) Vitamin D metabolite-mediated hypercalcemia in Wegener’s granulomatosis. Mayo Clin Proc 72(5):440–444PubMedCrossRefGoogle Scholar
  8. 8.
    Jourde N, Mancini J, Chiche L (2009) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 360(13):1358, Author reply 1359PubMedCrossRefGoogle Scholar
  9. 9.
    Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588PubMedCrossRefGoogle Scholar
  10. 10.
    Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24):1764–1769PubMedCrossRefGoogle Scholar
  11. 11.
    Haynes BF, Fishman ML, Fauci AS, Wolff SM (1977) The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of the literature. Am J Med 63(1):131–141PubMedCrossRefGoogle Scholar
  12. 12.
    Spalton DJ, Graham EM, Page NG, Sanders MD (1981) Ocular changes in limited forms of Wegener’s granulomatosis. Br J Ophthalmol 65(8):553–563PubMedCrossRefGoogle Scholar
  13. 13.
    Duncker G, Beigel A, Lehmann H (1982) Wegener’s granulomatosis: ocular manifestations, diagnosis and therapy. Klin Monbl Augenheilkd 181(3):184–187PubMedCrossRefGoogle Scholar
  14. 14.
    Stavrou P, Deutsch J, Rene C, Laws DE, Luqmani RA, Murray PI (1993) Ocular manifestations of classical and limited Wegener’s granulomatosis. Q J Med 86(11):719–725PubMedGoogle Scholar
  15. 15.
    Sadiq SA, Jennings CR, Jones NS, Downes RN (2000) Wegener’s granulomatosis: the ocular manifestations revisited. Orbit 19(4):253–261PubMedCrossRefGoogle Scholar
  16. 16.
    Harper SL, Letko E, Samson CM, Zafirakis P, Sangwan V, Nguyen Q, Uy H, Baltatzis S, Foster CS (2001) Wegener’s granulomatosis: the relationship between ocular and systemic disease. J Rheumatol 28(5):1025–1032PubMedGoogle Scholar
  17. 17.
    Kirker S, Keane M, Hutchinson M (1989) Benign recurrent multiple mononeuropathy in Wegener’s granulomatosis. J Neurol Neurosurg Psychiatry 52(7):918PubMedCrossRefGoogle Scholar
  18. 18.
    Monteiro MLR, Borges WIS, do Val Ferreira Ramos C, Lucato LT, Leite CC (2005) Bilateral optic neuritis in Wegener granulomatosis. J Neuroophthalmol 25(1):25–28PubMedCrossRefGoogle Scholar
  19. 19.
    Clayton AR, Savage CO (2000) What you should know about PR3-ANCA: evidence for the role of T cells in the pathogenesis of systemic vasculitis. Arthritis Res 2(4):260–262PubMedCrossRefGoogle Scholar
  20. 20.
    Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-UlrichK FAC, Pitann S, Gause A, Gross WL (2006) B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65(7):859–864PubMedCrossRefGoogle Scholar
  21. 21.
    Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1(2):147–153PubMedCrossRefGoogle Scholar
  22. 22.
    Walsh M, Jayne D (2007) Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 72(6):676–682PubMedCrossRefGoogle Scholar
  23. 23.
    Oristrell J, Bejarano G, Jordana R, Monteagudo M, Marí B, Casanovas A, Tolosa C (2009) Effectiveness of rituximab in severe Wegener’s granulomatosis: report of two cases and review of the literature. Open Respir Med J 3:94–99PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Cord Huchzermeyer
    • 1
  • Christian Mardin
    • 1
  • Leonard Holbach
    • 1
  • Jochen Zwerina
    • 2
  • Georg Schett
    • 2
  • Jürgen Rech
    • 2
  1. 1.Department of OphthalmologyUniversity of Erlangen-NurembergErlangenGermany
  2. 2.Department of Internal Medicine III, Institute for Clinical ImmunologyUniversity of Erlangen-NurembergErlangenGermany

Personalised recommendations